암을 일으킬 수 있음 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재)
발암성 물질
구분 1A, 1B
위험
H360
태아 또는 생식능력에 손상을 일으킬 수 있음
생식독성 물질
구분 1A, 1B
위험
H410
장기적 영향에 의해 수생생물에 매우 유독함
수생 환경유해성 물질 - 만성
구분 1
경고
P273, P391, P501
예방조치문구:
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P273
환경으로 배출하지 마시오.
P314
불편함을 느끼면 의학적인 조치·조언을 구하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
3
0
프라바스타틴 C화학적 특성, 용도, 생산
개요
Pravastatin is the third HMG-CoA reductase inhibitor introduced for the treatment of
atherosclerosis. Compared with lovastatin and simvastatin launched earlier, pravastatin is
equipotent as an HMG-CoA reductase inhibitor in vitro, yet it is reported to be more
tissue-selective.
화학적 성질
Off-white Cryst
용도
antiglaucoma,
일반 설명
Pravastatin, sodium 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoate (Pravachol), is the most rapid actingof the three HMG-CoA reductase inhibitor drugs, reachinga peak concentration in about 1 hour. The sodium salt of theβ-hydroxy acid is more hydrophilic than the lactone forms ofthe other two agents, which may explain this property. In addition,the open form of the lactone ring contributes to a morehydrophilic agent, which, in turn, results in less CNS penetration.This explains, in part, why pravastatin has fewer CNSside effects than the more lipophilic lactone ester of this classof agents. Absorption of pravastatin following oral administrationcan be inhibited by resins such as cholestyramine becauseof the presence of the carboxylic acid function on thedrug. The lactone forms of lovastatin and simvastatin are lessaffected by cholestyramine.
